How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

Table 1

Clinical characteristics of patients with T2D registered in the SIDIAP database.

Characteristics	All population ()	Secondary prevention patients ()	Primary prevention patients ()
Gender, male, (%)	204,707 (54.9)	56,882 (65.7)	147,825 (51.6)
Age (years), mean (SD)	70.1 (12.3)	74.8 (10.5)	68.7 (12.5)
Current smokers, (%)	52,744 (14.1)	11,058 (12.8)	41,686 (14.5)
BMI (kg/m^2), (%)
≥30	144,592 (44.9)	30,366 (40.3)	114,226 (46.4)
>45	3,905 (1.2)	521 (0.7)	3,384 (1.4)
Duration of diabetes (years), mean (SD)	9.3 (6.2)	10.9 (6.7)	8.8 (6.0)
HbA1c (%)^†, mean (SD)	7.12 (1.32)	7.16 (1.32)	7.10 (1.33)
, (%)	194,751 (59.0)	43,664 (56.6)	151,087 (59.8)
Hypertension, (%)	268,394 (71.9)	70,026 (80.9)	198,368 (69.2)
Dyslipidemia, (%)	223,785 (60.0)	56,194 (64.9)	167,591 (58.5)
eGFR (ml/min/1.73m^2)^†, (%)
≥60	241,958 (72)	45,598 (58)	196,360 (76)
30-60	80,978 (24)	27,651 (35)	53,327 (21)
<30	13,262 (4)	5,909 (7)	7,353 (3)
, (%)	51,429 (13.8)	17,126 (19.8)	34,303 (12.0)
T2D treatment, (%)
No antidiabetic medication	68,681 (18.4)	12,178 (14.1)	56,503 (19.7)
NIAD monotherapy	138,615 (37.1)	28,582 (33.0)	110,033 (38.4)
NIADs in combination	86,508 (23.2)	18,557 (21.4)	67,951 (23.7)
Insulin±NIAD	79,381 (21.3)	27,217 (31.5)	52,164 (18.2)

BMI: body mass index; eGFR: estimated glomerular filtration rate; NIAD: noninsulin antidiabetic drug; SD: standard deviation; T2D: type 2 diabetes; UACR: urine albumin-to-creatinine ratio; HbA1c: glycated haemoglobin. Secondary prevention: patients with established cardiovascular disease (ICD-10 codes for coronary heart disease, cerebrovascular disease, or peripheral arteriopathy). Primary prevention: patients without any ICD-10 code for cardiovascular disease. ^†There were 12% of missing data in the registration of HbA1c and 10% in the registration of eGFR.